Key Highlights

● Net revenue was about $257 million, up roughly 23% and a first-quarter record.

● Beverage revenue rose about 82% to roughly $101.5 million on the BrewDog acquisition.

● The net loss was about $40 million, attributed largely to non-cash charges.

● Management reaffirmed fiscal 2027 adjusted EBITDA guidance of $68 million to $75 million.

Tilray Brands (NASDAQ:TLRY) entered the latest stretch of cannabis earnings season earlier than most of its peers. On Thursday, October 8, the Nasdaq-listed company released results for the first quarter of its fiscal year 2027, covering the three months ended August 31. The headline was a record first-quarter revenue figure of about $257 million, a gain of roughly 23% from a year earlier.

What sits underneath that headline is a company that now earns most of its growth from outside traditional cannabis. Beverage sales, boosted by the acquisition of the BrewDog business, nearly doubled, and pharmaceutical distribution grew at a double-digit pace, while Canadian-centered cannabis revenue fell. The company also recorded an operating loss and a net loss, though it pointed to non-cash items and reaffirmed its adjusted EBITDA guidance for the year.

What did Tilray Brands report for its first quarter of fiscal 2027?

According to the company, Tilray Brands generated net revenue of about $257 million in the quarter, up from about $209.5 million in the same quarter last year. Gross margin dollars rose about 35% to roughly $77.5 million, and the gross margin percentage widened to about 30% from about 27%.

Further down the statement, the picture was weaker. The quarterly filing shows an operating loss of about $24 million, compared with operating earnings of about $2 million a year earlier, and a net loss of about $40 million, or 32 cents per share. A year earlier, the company reported small net earnings of about $1.5 million. The company said the loss reflected mostly non-cash charges, and it showed an adjusted net loss of about $3 million, or 2 cents per share, after those items were stripped out.

The filing itemized some of the costs behind the gap: restructuring costs of about $2.5 million, transaction costs of about $5 million and litigation costs of under $1 million. Those are the kinds of items companies typically exclude when presenting adjusted measures, which is why the adjusted and reported figures diverge so sharply this quarter.

How did the BrewDog acquisition change Tilray Brands' beverage segment?

Beverage was the standout. Segment revenue climbed about 82% to roughly $101.5 million, according to coverage of the release, and gross margin dollars were about $42 million at a margin of about 41%. The company attributed the surge largely to BrewDog, the craft brewer whose assets it bought earlier in the year.

The filing describes the BrewDog transactions in pieces: the United Kingdom business was acquired for about 33 million pounds, a brewery in Australia for a nominal price, five British pubs for a small amount and certain U.S. assets for roughly $9 million. Preliminary acquisition accounting was still in progress at the time of the filing, so the allocation of the price among inventory, brands and goodwill could change. The company also shows restricted cash in escrow linked to the BrewDog plc acquisition.

For a company that began as a cannabis grower, a beverage business of this scale is a major shift. Beverage revenue is now almost double that of the cannabis segment, and the higher margin percentage in the quarter indicates that the acquired operations are not diluting overall margins. Still, the acquired business is new to the portfolio, and integration costs, brewery capacity and consumer demand for craft beer remain variables to watch.

Why did Tilray Brands' cannabis revenue decline?

Cannabis revenue fell to about $56 million from about $64.5 million a year earlier, according to the figures reported. The company did not frame the decline as a demand problem; the segment's gross margin actually improved to about 39% from about 36%, which indicates that the company is earning more on each dollar of sales even as the dollar total drops.

Context from the prior fiscal year helps. In the year ended May 31, the company reported cannabis revenue of about $268 million, up about 8%, and noted that wholesale revenue had dropped sharply while international medical sales rose. Canadian adult-use sales are exposed to heavy price competition among licensed producers, and wholesale transactions between producers can swing widely from one quarter to the next.

International demand is the offsetting piece. Coverage of the quarter reported that revenue in Europe, the Middle East and Africa rose about 71%. That is consistent with the company's longstanding strategy of supplying medical cannabis to markets such as Germany, but the release as summarized did not give a precise international cannabis revenue figure for the quarter, so the net effect on the segment is unclear.

What drove the distribution and wellness segments at Tilray Brands?

Distribution revenue grew about 14% to roughly $84 million. This segment is largely the European pharmaceutical distribution business, CC Pharma, which supplies pharmacies. In the prior fiscal year, distribution was the largest segment by revenue at about $327 million, and its gross margin, though low at about 12%, was rising.

Wellness, which centers on hemp-based food products, was roughly flat at about $15 million. It remains the smallest of the four segments and was not a significant driver of either the gain or the loss in the quarter.

Taken together, the four segments show a company whose revenue base is more varied than it was a few years ago. Distribution and beverage together accounted for roughly 72% of quarterly revenue by simple arithmetic on the reported figures, while cannabis was about 22%. That mix matters for how results are interpreted: lower-margin distribution drives volume, while cannabis and beverage carry the higher gross margin percentages. A shift toward distribution would raise revenue but could pull the blended margin down.

How did Tilray Brands' adjusted EBITDA compare with the prior year?

Adjusted EBITDA came in at about $9 million, compared with about $10 million a year earlier. The company noted that the figure included about $1.7 million of global fuel surcharges, a cost that affected its distribution operations and one that it also called out in the prior fiscal year's fourth quarter.

The modest year-over-year decline stands out against a backdrop of much higher revenue and gross margin dollars. It indicates that operating expenses grew roughly as fast as the gross margin gain, which is common after acquisitions when general and administrative costs expand along with the business. Management has previously pointed to cost discipline and synergies, though the figures reviewed do not break out realized savings.

The company reaffirmed fiscal 2027 adjusted EBITDA guidance of $68 million to $75 million, which management described as double-digit growth over fiscal 2026's roughly $61 million. Reaching that range will require the remaining three quarters to deliver much more than the first.

What does the Tilray Brands balance sheet show after the quarter?

At August 31, cash and cash equivalents were about $215 million, down from about $226 million at the end of May. Including restricted cash and marketable securities, the company cited liquidity of about $221 million. Net cash used in operating activities was about $16.5 million in the quarter.

On the liability side, the filing lists a current portion of convertible debentures of about $59 million, down from about $79.5 million at the end of May, along with long-term debt of roughly $118 million and a current portion of long-term debt of about $15 million. Bank indebtedness was under $9 million, and lease liabilities totaled about $170 million. The company said it had cut debt by about $42 million year to date and ended the quarter in a net cash position.

Total assets were about $2.33 billion, of which goodwill was about $752 million and inventory about $329 million. Equity was roughly $1.6 billion. Large goodwill balances are a reminder that acquisition-heavy strategies can lead to later impairment charges if acquired businesses underperform, as occurred in the prior-prior fiscal year, when the company booked more than $2 billion of impairments.

How is Tilray Brands managing convertible notes and share issuance?

Two capital-markets activities appear in the quarterly filing. First, the company issued about 5 million shares to retire part of its convertible notes, which cleared debt with a carrying value of roughly $25 million. Second, it issued about 4.5 million shares through an at-the-market program, raising about $22 million in proceeds.

Using shares to settle debt and raise cash reduces borrowings but dilutes existing stock owners. As of October 6, the filing reports about 148 million shares outstanding. At the end of the prior fiscal year the count was about 132 million, and a one-for-ten reverse stock split took effect on December 2 of the previous year.

Whether that trade-off is favorable depends on the price at which shares are issued relative to the value of the debt retired, and the filing excerpt does not give a single answer. What can be said is that the company has opted to reduce leverage using equity rather than cash, which preserves liquidity for acquisitions and operations but expands the share count that earnings must be divided across.

What is Tilray Brands saying about U.S. cannabis rescheduling?

The company has repeatedly discussed the possibility of changes to federal cannabis rules in the United States. In its fiscal-year release in July, it said it was evaluating pathways into a federally compliant medical cannabis market and had drafted a medical-first U.S. platform blueprint, while noting that legal challenges and regulatory uncertainty continue.

At the first-quarter stage, Chief Executive Irwin Simon framed the company's position in different terms, saying in remarks quoted after the results that it is no longer reliant on a single market or a single regulatory event. That statement is consistent with the revenue mix described above, in which beverage and distribution now supply the majority of sales.

No specific, dated regulatory change has been identified as expected to affect results this fiscal year, and according to management's own framing its reaffirmed guidance does not depend on a U.S. opening, which remains an uncertainty.

How does the Tilray Brands quarter fit with its prior fiscal year?

The fiscal year that ended in May produced record net revenue of about $915.5 million, up about 11%, and a net loss of about $105 million, sharply narrower than the multibillion-dollar loss of the prior year, which was dominated by impairments. Adjusted EBITDA was about $61 million, up about 11%.

Against that base, the first quarter extends the same pattern: higher revenue, record gross margin dollars for a first quarter, but a bottom line still dragged by non-cash and transaction items. Management has said it expects over $1 billion of annual revenue in fiscal 2027. Annualizing the first quarter alone gives a figure slightly above that line by simple multiplication, though seasonality and acquisition timing make a straight-line calculation unreliable.

The fiscal fourth quarter of the prior year had been the strongest on revenue, at about $282 million, which included the early contribution of the BrewDog assets. The first quarter's sequential dip from that level is typical for a business with seasonal beverage and distribution patterns, though the release summary did not discuss it directly.

What should market participants watch next at Tilray Brands?

Several questions remain open. One is whether operating expenses stabilize so that the higher gross margin dollars flow through to EBITDA, since the first quarter produced a small decline despite a large revenue gain. A second is how the integration of BrewDog proceeds, including finalization of acquisition accounting and any restructuring costs.

A third is the trajectory of Canadian cannabis revenue, which fell again. Management has emphasized margin and international growth over domestic volume, but a shrinking segment reduces the base from which those gains are measured. A fourth is capital structure: the remaining convertible debentures are classified as current, so their settlement, by cash or shares, is a near-term event, and the at-the-market program remains a tool the company has shown it will use.

The company's next quarterly report, covering the period that includes the holiday season for beverages, should show whether the reaffirmed guidance range remains realistic.